Alimera Sciences announced that it has expanded its relationship with Horus Pharma, one of the company’s current distributors of Iluvien in Europe. Following the successful launch of Iluvien for diabetic macular edema (DME) in France by Horus Pharma, Alimera Sciences and Horus have agreed to expand their relationship to introduce Iluvien for both DME and noninfectious posterior uveitis (NIPU) in the Benelux countries of Belgium, the Netherlands, and Luxembourg.
Horus Pharma estimates that there are approximately 70,000 patients within the Benelux countries who may be affected by DME. With Iluvien approved for both DME and noninfectious posterior uveitis in the Benelux, Horus will undertake the process of applying for reimbursement in each Benelux nation for each indication over the next 12-18 months.
“We have enjoyed a productive and successful relationship with Horus Pharma, as they have obtained reimbursement for Iluvien in France and are executing an impressive launch in that territory,” Rick Eiswirth, president and CEO of Alimera, said in a company news release. “For those reasons, we made the decision to expand our relationship to include the Benelux countries where Horus also has considerable experience and reach. We look forward to potentially adding these three more countries to the list of anticipated Iluvien launches, as we continue to execute on our global commercial expansion strategy.”